English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

This research is planned to synthesize and characterize interpenetrating polymer network (IPN) nanogels by combining natural (β-cyclodextrin) and synthetic (Polyvinyl alcohol) polymers by free radical polymerization utilizing N,N-methylenebisacrylic acid (MBA) and 2-acrylamido-2-methylpropane sulfonic acid (AMPS). FTIR, DSC, and TGA were employed to characterize the thermal stability of components and the conception of cross-linked networks. The porosity and amorphousness of the structure were shown using SEM and XRD. The entrapment efficiency of prepared nanogels was found to be more than 70%. The enormous increase in rosuvastatin solubility compared to the usual formulation led to a significant development in the drug’s release profile and released more than 90% of the drug within 5–30 minutes. As compared to the commercially available tablet (Rovista®), triglyceride and total cholesterol levels were significantly lower in hyperlipidemic rats treated with RST-loaded nanogel. Therefore, the atherosclerosis index of nanogels demonstrated a considerable improvement in pharmacodynamic effectiveness in animals.

polymer-plastics technology and materials

Development, in vitro and in vivo evaluation of β-cyclodextrin/Polyvinyl alcohol-co-poly (2-acrylamide-2-methylpropane sulfonic acid) cross-linked hybrid IPN-nanogels to improve the dissolution and absorption of anti-hyperlipidemic drug